The short version of Secretagogue fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-11 and is reviewed periodically as new material appears.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
In 2019, the FDA and EMA approved givosiran for the treatment of adults with acute hepatic porphyria (AHP). The FDA also granted givosiran a breakthrough therapy designation, priority review designation, and orphan drug designation for the treatment of acute hepatic porphyria (AHP) in November 2019. By 2020, givosiran received EMA approval. Givosiran is an siRNA that breaks down aminolevulinic acid synthase 1 (ALAS1) mRNA in the liver. Breaking down ALAS1 mRNA prevents toxins (responsible for neurovisceral attacks and AHP disease) such as aminolevulinic acid (ALA) and porphobilinogen (PBG) from accumulating. To facilitate entry into the cytoplasm, givosiran uses GalNAc ligands and enters into liver cells. The medication is administered subcutaneously by a healthcare professional with dosing based on body weight. Warnings and precautions include risk of anaphylactic reactions, hepatic toxicity, renal toxicity and injection site reactions. Lumasiran was approved as a siRNA-based medication in 2020 for use in both the European Union and the United States. This medication is used for the treatment of primary hyperoxaluria type 1 (PH1) in pediatric and adult populations. The drug is designed to reduce hepatic oxalate production and urinary oxalate levels through RNAi by targeting hydroxyacid oxidase 1 (HAO1) mRNA for breakdown. Lowering HAO1 enzyme levels reduces the oxidation of glycolate to glyoxylate (which is a substrate for oxalate). Lumasiran is administered subcutaneously by a healthcare professional with dosing based on body weight.
=== Parathyroid carcinoma === In extremely rare cases, a malignant tumor may develop within the parathyroid gland. They can be detected intraoperatively, imaging, or through blood testing. A thick fibrous capsule is usually present around the gland, as opposed to the thin capsule present in benign adenomas. Parathyroid hormone level is often greater in carcinomas than in benign disorders.
=== Independent Namibia === When Namibia gained its independence in 1990, SWAPO became the dominant political party. Though the organisation rejected the term South West Africa and preferred to use Namibia, the organisation's original name—derived from the territory's old name—was too deeply rooted in the independence movement to be changed. However, the original full name is no longer used; only the acronym remains. SWAPO, and with it much of Namibia's government and administration, continues to be dominated by the Ovambo ethnic group, despite "considerable efforts to counter [that] perception". SWAPO president Sam Nujoma was declared Namibia's first President after SWAPO won the inaugural election in 1989. A decade later, Nujoma had the constitution changed so he could run for a third term in 1999, as it limits the presidency to two terms. In 2004, the SWAPO presidential candidate was Hifikepunye Pohamba, described as Nujoma's hand-picked successor. In 2014, the SWAPO presidential candidate was Hage Geingob, who was the vice-president of SWAPO. In 2019 presidential election, president Geingob won his second five-year term as Namibian president.
== Bowfin body-shape evolution and development == The first fish lacked jaws and used negative pressure to suck their food in through their mouths. The jaw in the bowfin is a result of its evolutionary need to be able to catch and eat bigger and more nutritious prey. As a result of being able to gather more nutrients, the bowfin is able to live a more active lifestyle. The jaw of a bowfin has several adaptations. The maxilla and premaxilla are fused and the posterior chondrocranium articulates with the vertebra, which allows the jaw freedom to rotate. The suspensorium includes several bones and articulates with the snout, brain case, and mandible. When the jaw opens, epaxial muscles lift the chondrocranium, which is attached to the upper jaw, while adductor muscles act to close the lower jaw. This ability to open and close the jaw helps the bowfin to be an active predator that can catch bigger prey and digest them. The vertebral column in bowfin is ossified and in comparison to earlier fish, the centra are the major support for the body, whereas in earlier fish, the notochord was the main form of support. In the bowfin, neural spines and ribs also increase in prominence, an evolutionary aspect that helps provide additional support and stabilize unpaired fins. The evolution of the vertebral column allows the bowfin to withstand lateral bending that puts the column under compression without breaking. This, in turn, allows the bowfin to have more controlled and powerful movements, in comparison to fish that have only a notochord.
== Discovery == An in silico search for potential small open-reading-frames (sORFs) within 16S ribosomal RNA-encoding short peptides (20–40 amino acids) was conducted in the Pinchas Cohen lab at University of Southern California. Six sequences encoding 20–38 amino-acid-long peptides were identified, which were named SHLP 1–6. The endogenous SHLPs were detected by immunoblots and their transcripts were validated by both qPCR and northern blot.
Sources: en.wikipedia.org
== Committees and governance == IUPAC is governed by several committees that all have different responsibilities. The committees are as follows: Bureau, CHEMRAWN (Chem Research Applied to World Needs) Committee, Committee on Chemistry Education, Committee on Chemistry and Industry, Committee on Printed and Electronic Publications, Evaluation Committee, Executive Committee, Finance Committee, Interdivisional Committee on Terminology, Nomenclature and Symbols, Project Committee, and Pure and Applied Chemistry Editorial Advisory Board. Each committee is made up of members of different National Adhering Organizations from different countries. The steering committee hierarchy for IUPAC is as follows:
The modifications covered in this diagram have to do with stereochemistry and the assignment of unique Cahn-Ingold-Prelog R/S assignments to complex analogues of fentanyl. The stereochemistry of fentanyl analogues can seem at first counter-intuitive, because of the complex and unique nature of the reasoning organic chemists must develop to internalize complex three dimensional geometries such as those needed to comprehend stereochemistry. Thankfully these images follow a simple procedure for organizing a potential analogue of fentanyl into the total number of unique stereoisomers, the number of true stereocenters on the molecule, and the number of Cahn-Ingold-Prelog R/S assignments that are appropriate for that analogue. The procedure used in the analysis of stereochemistry in these series of images is the following:
Long-term comas can have a significant impact on a patient's family. Families of coma patients often have idealized images of the outcome based on Hollywood movie depictions of coma. Adjusting to the realities of ventilators, feeding tubes, bedsores, and muscle wasting may be difficult. Treatment decisions often involve complex ethical choices and can strain family dynamics.
=== First Empire === September 15, 1807: If a husband goes bankrupt, the wife's personal assets are also affected. March 17, 1808: Decree organizing the university bans women from entering colleges or lycées. March 29, 1809: Decree organizing Napoleon's imperial houses in Écouen and Saint-Denis to educate battlefield orphans' daughters as "future mothers." 1810: Penal Code of 1810 includes measures specific to women or differentiates penalties by sex. January 19, 1811: Decree on foundlings, abandoned children, and poor orphans, with education differing by sex. October 15, 1812: Decree on the Théâtre-Français's oversight, organization, administration, accounting, police, and discipline, admitting equal numbers of male and female students. February 5, 1813: Organic Senatus-Consultum on imperial regency and the coronation of the empress and prince imperial, prioritizing the empress for regency and barring her remarriage.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.